Lipocine Operating Margin from 2010 to 2025

LPCN Stock  USD 3.56  0.12  3.26%   
Lipocine Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to drop to -0.11.
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 11.8 M, as well as many indicators such as Price To Sales Ratio of 2.21, Dividend Yield of 0.0 or PTB Ratio of 1.3. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Latest Lipocine's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Lipocine over the last few years. It is Lipocine's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.44 %10 Years Trend
Very volatile
   Operating Profit Margin   
       Timeline  

Lipocine Operating Margin Regression Statistics

Arithmetic Mean(15.83)
Geometric Mean3.33
Coefficient Of Variation(135.86)
Mean Deviation16.82
Median(0.11)
Standard Deviation21.50
Sample Variance462.33
Range84.4781
R-Value0.08
Mean Square Error492.54
R-Squared0.01
Significance0.78
Slope0.34
Total Sum of Squares6,935

Lipocine Operating Margin History

2025 -0.11
2024 -0.1
2023 6.29
2022 -24.24
2020 0.19
2019 -78.19

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as Operating Margin, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
2.097
Quarterly Revenue Growth
15.15
Return On Assets
(0.03)
Return On Equity
0.0004
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.